Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

The transcript discusses Eli Lilly's acquisition of Scorpion Therapeutics' breast cancer program, highlighting its alignment with their oncology efforts. It covers Eli Lilly's diverse portfolio, including diabetes, immunology, and neuroscience. The company's M&A strategy focuses on early-stage, smaller deals to strengthen their pipeline. The development of oral weight loss drugs is explored, emphasizing their potential market impact. The transcript also touches on the political environment's influence on pricing policies and Eli Lilly's Alzheimer's treatment, showcasing their commitment to addressing neurodegenerative diseases.

What role does Eli Lilly see for itself in the broader pharmaceutical market?

How does Eli Lilly's approach to obesity treatment differ from its other therapeutic areas?

What are the implications of the incoming administration's health policies for Eli Lilly?

What progress has Eli Lilly made in the field of Alzheimer's treatment?